ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.

Trump administration says it is trying to prevent war but raises eyebrows by calling for commitments from Australia and Japan ...

Breaking news and top stories from Asia-Pacific. The latest on the economy, politics, government, and business ...